New clinical trial evaluates whether aerobic exercise alone or when combined with transcranial direct current stimulation improves cognitive function in treatment resistant schizophrenia. Publication date context: 2026-02-19.
The study, listed on ClinicalTrials.gov as NCT07404319, is sponsored by Kit Wa Chan. It tests four arms to determine the cognitive effect of exercise and of tDCS in people with schizophrenia and cognitive impairment who have not responded to standard treatments. The trial status is not yet recruiting, signaling future enrollment and data collection. Details about the study and the intervention arms are publicly accessible on ClinicalTrials.gov and may be used by clinicians and regulators to monitor potential device use in this area.
The interventions include a behavioral arm focused on aerobic exercise and a stretching education control. In addition to the behavioral arms, the trial uses device based therapy with active tDCS and a sham tDCS condition, enabling comparison of real and placebo neurostimulation effects. The combination of exercise and tDCS represents a potential approach to address cognitive deficits that limit daily functioning in patients with treatment resistant schizophrenia.
Readers may follow related updates through two internal posts on our site and explore the official record at ClinicalTrials.gov: Exercise neuromodulation updates and Regulatory review of tDCS in schizophrenia. For more context you can view the official listing at ClinicalTrials.gov: NCT07404319.
What is the study about?
The trial seeks to understand cognitive outcomes in people with schizophrenia who have cognitive impairment and a treatment resistant form of the condition. It incorporates a behavioral arm using aerobic exercise and a stretching education control, alongside device based arms with active tDCS and sham tDCS to assess added effects on cognition. The conditions studied include schizophrenia and cognitive impairment, with treatment resistant schizophrenia explicitly noted. Kit Wa Chan sponsors the project and the public record indicates the study is not yet recruiting.
What are the interventions?
Interventions consist of four arms: Behavioral Aerobic Exercise, Behavioral Stretching and Education Control, Device Active tDCS, and Device Sham tDCS. The design aims to separate effects from behavior and from device based neuromodulation on cognitive outcomes.
How is the trial designed?
The study uses parallel arms involving both behavioral and device based modalities. The behavioral options are aerobic exercise and stretching education control, while the device options are active tDCS and sham tDCS. The public listing does not provide details on randomization or allocation, and the status remains not yet recruiting as listed.
Who should care?
Clinicians treating schizophrenia and cognitive impairment, researchers in neuromodulation and exercise therapy, and regulatory professionals will watch this trial for signs of cognitive benefit and safety. If results show meaningful improvement and acceptable safety, regulators may consider guidance on the use of tDCS devices in combination with exercise for selected patient groups, pending governance and labeling updates. Patients and caregivers may track enrollment options when the trial is active.
FAQ
- 1. What is the purpose of the trial? To compare cognitive outcomes from aerobic exercise alone versus exercise with tDCS in treatment resistant schizophrenia.
- 2. What arms are tested? Aerobic exercise, stretching education control, active tDCS, and sham tDCS.
- 3. Where can I find the official listing? On ClinicalTrials.gov with identifier NCT07404319.
Conclusion
The trial addresses a meaningful question about combining physical and neuromodulation therapies for cognitive deficits in a difficult to treat population. If future results demonstrate benefit and safety, clinicians could consider the approach with appropriate regulatory and ethical oversight and under manufacturer labeling and guidance. Readers should await trial outcomes for robust conclusions and potential regulatory implications for device use in psychiatry.
Disclaimer
This article is intended for professional use and is not legal advice. It reflects information from clinical trial records and related sources available at the time of publication.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07404319?term=medical+device